Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of the Safety and Preliminary Efficacy of Intramedullary Spinal Cord Transplantation of Human Central Nervous System (CNS) Stem Cells (HuCNS-SC) in Subjects With Thoracic (T2-T11) Spinal Cord Trauma

Trial Profile

A Phase I/II Study of the Safety and Preliminary Efficacy of Intramedullary Spinal Cord Transplantation of Human Central Nervous System (CNS) Stem Cells (HuCNS-SC) in Subjects With Thoracic (T2-T11) Spinal Cord Trauma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adult neural stem cells (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions
  • Sponsors StemCells
  • Most Recent Events

    • 09 Jul 2015 According to StemCells media release, data from this trial has been presented at the International Society for Stem Cell Research (ISSCR) 2015 Annual Meeting.
    • 17 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 May 2015 Results were presented in StemCells media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top